Safety and Efficacy of Ruxolitinib for COVID-19

University of Colorado, Denver

Overview

This study plans to learn more about the effects of a medicine called ruxolitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ruxolitinib is FDA-approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. This study intends to define the impact of ruxolitinib on the severity and progression of COVID-19. This drug might to lower the hyperinflammation caused by the virus, which would prevent damage to the lungs and possibly other organs. The study will recruit patients who have been diagnosed with COVID-19. The goal is to recruit 80 patients.

This is an adaptive Phase 2/3 clinical trial, with a focus on the assessment of safety in the first 20 participants (Phase 2), followed by a much broader assessment of efficacy, while continuing to monitor safety, in an additional 60 participants (Phase 3, total participants across Phase 2/3 n=80). Both phases are single arm, open label, and occur at a single site at the University of Colorado Hospital (UCH). Data from participants in this study will be compared with data from other COVID-19 patients not receiving ruxolitinib. Study participants will receive 10 mg twice daily of ruxolitinib for 14 days and will be followed for up to 29 days.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

COVID-19

Interventions

RuxolitinibDRUG

Participants will receive 10 mg ruxolitinib twice daily.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged 18 - 89 years at time of enrollment * Hospitalized (or documented plan to hospitalize if patient is in the emergency department) with symptoms suggestive of COVID-19 * lllness of any duration that meets each of the following: * Evidence of pneumonia, including radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) or clinical assessment (rales/crackles on exam) * Requires supportive care, including non-invasive supplemental oxygen * Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay within 7 days of enrollment * Understands and agrees to comply with planned study procedures * Provides informed consent signed by study patient or legally acceptable representative Exclusion Criteria: * Absolute platelet counts are less than 75 x 10\^9/L * Absolute neutrophil count is less than 0.5 x 10\^9/L * Hemoglobin is less than 8 g/dL * Severe renal impairment defined by serum creatinine greater than 2 mg/dL or CrCl less than 30 mL/min * Treatment with other JAK inhibitors, strong CYP3A4 inhibitors, biologic disease-modifying anti-rheumatic drugs (DMARDs, including anti-IL-6 or anti-IL-6R antibodies), or potent immunosuppressants such as azathioprine and cyclosporine concurrently or within the past 5 days. Note: recent or concurrent treatment with hydroxychloroquine or chloroquine is allowable, as these are 'non-biologic' DMARDs with potential antiviral activity. * History of HIV infection and on active immunosuppressant therapy * Current hematological or solid organ malignancy and on active immunosuppressant therapy * Active tuberculosis (TB) infection or known or suspected systemic bacterial or fungal infection * Pregnancy or breast feeding * Known allergy to ruxolitinib * In the opinion of the investigator, they are unlikely to survive for \>48 hours from screening * Any physical examination findings and/or history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study Additional Exclusion Criteria for Phase 2 only: * Invasive oxygen supplementation, including mechanical ventilation and extracorporeal membrane oxygenation (ECMO)

Outcomes

Primary Outcomes

Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)

Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening. AEs will be collected and graded daily and cumulative incidence will be reported.

Time frame: Day 0 (screening) through Day 29

Phase 2: Cumulative incidence of serious adverse events (SAEs)

An SAE is defined as an AE that is life-threatening or results in death, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. SAEs will be collected and graded daily and cumulative incidence will be reported.

Time frame: Day 0 (screening) through Day 29

Phase 2: Changes in white blood cell count (CBC) through Day 15

Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as standard of care (SOC). Mean changes from baseline to Day 15 will be reported.

Time frame: Day 1 to Day 15

Phase 2: Changes in hemoglobin through Day 15

Time frame: Day 1 to Day 15

Phase 2: Changes in platelets through Day 15

Time frame: Day 1 to Day 15

Phase 2: Changes in creatinine through Day 15

Time frame: Day 1 to Day 15

Phase 2: Changes in glucose through Day 15

Time frame: Day 1 to Day 15

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Phase 2: Change in the 8-point ordinal scale

Time frame: Day 1 to Day 29

Phase 2: Change in National Early Warning Score (NEWS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Change in the 8-point ordinal scale

Time frame: Day 1 to Day 29

Phase 3: Change in National Early Warning Score (NEWS)

Time frame: Day 1 to Day 29 or hospital discharge, whichever is first

Phase 3: Time to an improvement of one category using the 8-point ordinal scale

Time frame: Day 1 to Day 29 or hospital discharge, whichever is first

Phase 3: Time to an improvement of two categories using the 8-point ordinal scale

Time frame: Day 1 to Day 29 or hospital discharge, whichever is first

Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)

Time frame: Day 0 (screening) through Day 29

Phase 3: Cumulative incidence of serious adverse events (SAEs)

Time frame: Day 0 (screening) through Day 29

Phase 3: Duration of hospitalization

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Duration of new oxygen use

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Duration of new ventilator or ECMO use

Time frame: Day 1 to Day 29 or hospital discharge, whichever is first

Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Incidence of new oxygen use

Time frame: Day 1 to Day 29 or hospital discharge, whichever is first

Phase 3: Incidence of new ventilator use

Time frame: Day 1 to Day 29 or hospital discharge, whichever is first

Phase 3: Number of oxygen free days

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Number of ventilator or ECMO free days

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: 14 day mortality rate

Time frame: Day 1 through Day 15

Phase 3: 28 day mortality rate

Time frame: Day 1 through Day 29

Phase 3: Changes in white blood cell count (CBC) through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in hemoglobin through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in platelets through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in creatinine through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in glucose through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in prothrombin time (PT) through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in total bilirubin through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in ALT through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in AST through Day 15

Time frame: Day 1 to Day 15

Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)

Safety assessment via standard blood chemistry and metabolic panels will be performed daily as recommended by participant's physician as SOC. Mean changes from baseline to EOS will be reported.

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in hemoglobin through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in platelets through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in creatinine through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in glucose through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in total bilirubin through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in ALT through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first

Phase 3: Changes in AST through End of Study (EOS)

Time frame: Day 1 through Day 29 or hospital discharge, whichever is first